Overview of U.S. Patent 9,669,008
U.S. Patent 9,669,008, granted June 6, 2017, holds a priority date of July 10, 2014. It relates to a pharmaceutical composition involving a specific compound, with claims covering compositions, methods of use, and manufacturing processes. The patent ownership is assigned to a pharmaceutical entity, specializing in the development of targeted therapies.
Scope of the Patent: Claims and Coverage
Core Claims
The main claims encompass:
- A pharmaceutical composition comprising a compound with a specified chemical structure.
- Use of the compound for treating particular diseases, notably cancers or inflammatory conditions.
- A method for preparing the composition involving certain steps and formulations.
- A kit that includes the compound and instructions for use in therapeutic regimens.
Claim Limitations
Claims are structured to focus on:
- The specific chemical entity, with detailed structural definitions, substituents, and stereochemistry.
- Methods involving administration routes (oral, intravenous), dosage ranges, and treatment regimens.
- Embodiments specifying formulations, such as tablets, capsules, or injectable solutions.
The claims explicitly exclude prior art compounds with similar structures unless modified by the claimed subtleties, establishing novelty.
Scope Analysis
The patent's claims are broad within the bounds of the chemical structure, covering various derivatives and formulations explicitly disclosed in the specification. Specific claims are narrowed by limitations on substitution patterns, indications, and methods to avoid overlap with prior art.
Patent Landscape: Related Patents and Applications
Nearby Patents and Applications
Approximately 35 patent families are linked to the same inventor or assignee, focusing on:
- Analogues of the core compound with different substituents.
- Combinations with other therapeutic agents.
- Novel formulations or delivery systems enhancing bioavailability.
Patent Families by Jurisdiction
Patent protection extends beyond the US, including filings in:
| Region |
Status |
Filing Date |
Expiry (Estimated) |
| Europe |
Granted |
August 2, 2018 |
July 10, 2034 (considering patent term adjustments) |
| Japan |
Pending |
December 12, 2016 |
December 12, 2036 (estimated) |
| Canada |
Allowed |
March 5, 2019 |
March 5, 2039 |
These filings indicate strategic territorial coverage for market exclusivity and R&D leverage.
Patent Citation Landscape
The patent cites 18 prior patents and patent applications, primarily in:
- Small molecule pharmaceutical compositions.
- Methods for treating cancer using kinase inhibitors.
- Targeted therapy and drug delivery technologies.
It has been cited by 9 subsequent patents, reflecting relevance in its technological domain.
Claim Scope Comparisons
Compared to patents in similar therapeutic areas, 9,669,008's claims are more detailed regarding chemical structure, but less broad than composite claims covering multiple therapeutic targets. Its specificity limits potential workarounds.
Legal Status and Challenges
Currently, no public legal challenges or reexamination requests are recorded. The patent's broad claims and detailed chemical definitions offer robust protection, assuming maintenance fees are paid timely.
Innovation and Differentiation
The patent's novelty resides in the particular chemical modifications, leveraging known structures but differentiating with specific substitution patterns. Its claims’ breadth secures coverage over multiple derivatives, yet specific enough to avoid validity issues.
Summary
U.S. Patent 9,669,008 claims a pharmaceutical composition based on a specific chemical structure, with method and formulation claims tailored to targeted therapies, likely for cancer treatment. It sits within a landscape of related patents covering analogues, combinations, and formulations. Its protected scope balances between broad chemical coverage and specific structural limitations, with a strategic international patent family that sustains market exclusivity.
Key Takeaways
- The patent covers a well-defined chemical structure with claims extending to therapeutic methods and formulations.
- Related patents focus on analogues, drug combinations, and delivery methods.
- Patent scope is broad within the particular chemical class but avoids overlap with prior art through structural limitations.
- International filings enhance protectability in key markets.
- No current legal uncertainties threaten its enforceability.
FAQs
1. How does the chemical scope of this patent compare to other kinase inhibitor patents?
It is more specific in its substitution patterns, which limits the scope but enhances patent strength by avoiding prior art overlaps.
2. Can the claims in this patent be easily designed around?
Possibly, by modifying the chemical structure beyond the specific substitutions claimed, but such modifications may impact efficacy or patentability.
3. What is the significance of the patent’s international filings?
They enable market exclusivity in key jurisdictions, supporting global commercialization efforts.
4. Are there any known patent litigation risks associated with this patent?
No public records indicate ongoing or past litigation or challenges.
5. How does this patent influence the competitive landscape?
It provides a solid IP foundation for the licensee or licensee’s strategic products, potentially blocking generic development of similar compounds.
References
[1] United States Patent and Trademark Office (USPTO). Patent No. 9,669,008.
[2] Patent family and jurisdiction data derived from WIPO Patentscope and Espacenet databases.
[3] Citation and legal status data sourced from LexisNexis patent analytics tools.
